discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna Inc.“In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), will meet to discuss the totality of the safety and effectiveness data provided by Moderna for their EUA submission,” said FDA Commissioner Stephen M.
Hahn, M.D.Background materials -- including the meeting agenda and committee roster -- will likely be made available to the public no later than two business days prior to the meeting on Dec.